Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated August 14, 2024, serves as a report of foreign private issuer pursuant to Rule 13a-16 of the Securities Exchange Act of 1934. The document discloses share transactions by board members, executives, and associated persons in compliance with Article 19 of Regulation No. 596/2014 on market abuse. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 69,000 people across 80 countries.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is strictly a disclosure of insider trading activity.
Material Changes and Transaction Details
The filing reports a specific transaction involving a Board member:
- Person: Liselotte Hyveled (Member of the Board of Directors)
- Transaction Type: Sale of shares
- Instrument: Novo Nordisk B Shares (DK0062498333)
- Volume: 8,480 shares
- Price: DKK 895.50 per share
- Total Value: DKK 7,593,840
- Date: August 13, 2024
- Exchange: Nasdaq Copenhagen
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a routine regulatory disclosure of executive trading.
Investor Verification Points
- Verify the total shareholding of Liselotte Hyveled post-transaction to assess remaining exposure.
- Confirm the transaction date (August 13, 2024) against the company's trading window policies.
- Review the aggregate value of the sale (DKK 7.6 million) relative to the executive's total compensation package.